ABCELLERA BIOLOGICS INC. 00288U106 CA00288U1066 06/11/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Say-on-Pay; SECTION 14A SAY-ON-PAY VOTES ISSUER 30275938 0 FOR 30275938 FOR ABIVAX SA 00370M103 US00370M1036 05/11/2026 Approval of the elements of remuneration paid during or awarded in respect of the 2025 financial year to Mrs. Sylvie Gregoire due to her mandate as Chairman of the Board of Directors. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABIVAX SA 00370M103 US00370M1036 05/11/2026 Approval of the elements of remuneration paid during or awarded for the 2025 financial year to Mr. Marc De Garidel due to his mandate as Chief Executive Officer. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABIVAX SA F00182109 FR0012333284 05/11/2026 Approval of the elements of remuneration paid during or awarded in respect of the 2025 financial year to Mrs. Sylvie Gregoire due to her mandate as Chairman of the Board of Directors. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABIVAX SA F00182109 FR0012333284 05/11/2026 Approval of the elements of remuneration paid during or awarded for the 2025 financial year to Mr. Marc De Garidel due to his mandate as Chief Executive Officer. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ACADIA PHARMACEUTICALS INC. 004225108 US0042251084 05/29/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 43102442 0 FOR 43102442 FOR ALIGOS THERAPEUTICS, INC. 01626L204 US01626L2043 06/25/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (''Say-on-Pay''); and SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ALIGOS THERAPEUTICS, INC. 01626L204 US01626L2043 06/25/2026 To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one year, every two years or every three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ALKERMES PLC G01767105 IE00B56GVS15 05/20/2026 To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ARCUS BIOSCIENCES, INC. 03969F109 US03969F1093 06/11/2026 To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ARGENX SE 04016X101 US04016X1019 05/06/2026 The 2025 remuneration report (advisory non-binding voting item). SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ARROWHEAD PHARMACEUTICALS, INC. 04280A100 US04280A1007 03/19/2026 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 BEONE MEDICINES, LTD. (FKA BEIGENE) 07725L102 US07725L1026 06/11/2026 That, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, for the fiscal year ended December 31, 2025 be and is hereby approved. SECTION 14A SAY-ON-PAY VOTES ISSUER 8849435 0 FOR 8849435 FOR BEONE MEDICINES, LTD. (FKA BEIGENE) CH1391448177 06/11/2026 That, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, for the fiscal year ended December 31, 2025 be and is hereby approved. SECTION 14A SAY-ON-PAY VOTES ISSUER 93429 0 FOR 93429 FOR BICYCLE THERAPEUTICS PLC 088786108 US0887861088 06/17/2026 To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 10885357 0 FOR 10885357 FOR BIONTECH SE 09075V102 US09075V1026 05/15/2026 Resolution on the approval of the Compensation Report. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 CELCUITY INC. 15102K100 US15102K1007 05/14/2026 To approve, on an advisory basis, named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 7915792 0 FOR 7915792 FOR CELLDEX THERAPEUTICS, INC. 15117B202 US15117B2025 06/25/2026 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 CERUS CORPORATION 157085101 US1570851014 06/02/2026 Advisory Votes on Executive Compensation: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 CERYVYN THERAPEUTICS LTD. (FKA OPTHEA LTD.) 68386J208 US68386J2087 11/11/2025 Adoption of Remuneration Report. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 CERYVYN THERAPEUTICS LTD. (FKA OPTHEA LTD.) AU0000478117 11/11/2025 Adoption of Remuneration Report. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 COMPASS PATHWAYS PLC 20451W101 US20451W1018 05/27/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended 31 December 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 CRINETICS PHARMACEUTICALS INC. 22663K107 US22663K1079 06/18/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 CYTOMX THERAPEUTICS, INC. 23284F105 US23284F1057 06/17/2026 To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 CYTOMX THERAPEUTICS, INC. 23284F105 US23284F1057 06/17/2026 To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 DBV TECHNOLOGIES S.A. 23306J309 US23306J3095 06/03/2026 Advisory opinion on the compensation of named Executive Officers other than the Chief Executive Officer. SECTION 14A SAY-ON-PAY VOTES ISSUER 1461425 0 FOR 1461425 FOR DBV TECHNOLOGIES S.A. 23306J309 US23306J3095 06/03/2026 Approval of the fixed, variable And non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Michel De Rosen, Chairman of the Board Of Directors. SECTION 14A SAY-ON-PAY VOTES ISSUER 1461425 0 FOR 1461425 FOR DBV TECHNOLOGIES S.A. 23306J309 US23306J3095 06/03/2026 Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Daniel Tasse, Chief Executive Officer. SECTION 14A SAY-ON-PAY VOTES ISSUER 1461425 0 FOR 1461425 FOR DBV TECHNOLOGIES S.A. F2927N109 FR0010417345 06/03/2026 Advisory opinion on The compensation of named executive officers other than the Chief Executive Officer. SECTION 14A SAY-ON-PAY VOTES ISSUER 16161038 0 FOR 16161038 FOR DBV TECHNOLOGIES S.A. F2927N109 FR0010417345 06/03/2026 Approval of the fixed, variable And non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Michel De Rosen, Chairman of the Board Of Directors. SECTION 14A SAY-ON-PAY VOTES ISSUER 16161038 0 FOR 16161038 FOR DBV TECHNOLOGIES S.A. F2927N109 FR0010417345 06/03/2026 Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Daniel Tasse, Chief Executive Officer. SECTION 14A SAY-ON-PAY VOTES ISSUER 16161038 0 FOR 16161038 FOR DENALI THERAPEUTICS INC. 24823R105 US24823R1059 06/03/2026 Advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 3731695 0 FOR 3731695 FOR DIANTHUS THERAPEUTICS, INC. 252828108 US2528281080 05/21/2026 To approve, on an advisory basis, the compensation paid to our named executive officers; and SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 DISC MEDICINE, INC. 254604101 US2546041011 06/18/2026 To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 DYNE THERAPEUTICS, INC. 26818M108 US26818M1080 06/05/2026 To vote, on an advisory basis, to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 EDGEWISE THERAPEUTICS INC. 28036F105 US28036F1057 06/04/2026 Conduct an advisory vote on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ENLIVEN THERAPEUTICS, INC. 29337E102 US29337E1029 06/09/2026 To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ENLIVEN THERAPEUTICS, INC. 29337E102 US29337E1029 06/09/2026 To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 IDEAYA BIOSCIENCES, INC. 45166A102 US45166A1025 06/16/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 IMMUNOVANT, INC. 45258J102 US45258J1025 08/27/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 INCYTE CORPORATION 45337C102 US45337C1027 06/08/2026 Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 31337785 0 FOR 31337785 FOR INSMED INCORPORATED 457669307 US4576693075 05/13/2026 An advisory vote on the 2025 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 IONIS PHARMACEUTICALS, INC. 462222100 US4622221004 06/04/2026 To make an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 KALA BIO, INC. 483119301 US4831193010 01/30/2026 Approval of a non-binding advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 2057789 0 FOR 2057789 FOR KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC G52694109 GB00BRXB0C07 05/29/2026 To approve, on an advisory (non-binding) basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 2855926 0 FOR 2855926 FOR KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC G52694109 GB00BRXB0C07 05/29/2026 To approve, on an advisory (non-binding) basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2855926 0 FOR 2855926 FOR KODIAK SCIENCES INC. 50015M109 US50015M1099 06/02/2026 Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 19919186 0 FOR 19919186 FOR KYMERA THERAPEUTICS, INC. 501575104 US5015751044 06/24/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers; and SECTION 14A SAY-ON-PAY VOTES ISSUER 8657242 0 FOR 8657242 FOR MADRIGAL PHARMACEUTICALS INC. 558868105 US5588681057 06/17/2026 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 2141701 0 FOR 2141701 FOR MERUS N.V. N5749R100 NL0011606264 12/09/2025 Non-binding advisory proposal to approve certain compensation arrangements SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To hold a non-binding advisory vote on whether future non-binding advisory votes on the executive compensation paid by the company to its named executive officers should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 NURIX THERAPEUTICS, INC. 67080M103 US67080M1036 05/15/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 4597916 0 FOR 4597916 FOR PRAXIS PRECISION MEDICINES, INC. 74006W207 US74006W2070 06/10/2026 To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the compensation tables and narrative discussion. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 PRELUDE THERAPEUTICS INCORPORATED 74065P101 US74065P1012 06/09/2026 Advisory vote to approve the 2025 compensation for the company's named executive officers (say-on-pay). SECTION 14A SAY-ON-PAY VOTES ISSUER 10123824 0 FOR 10123824 FOR PRELUDE THERAPEUTICS INCORPORATED 74065P101 US74065P1012 06/09/2026 Advisory vote on the frequency of advisory votes on named executive officer compensation (say-on-frequency). SECTION 14A SAY-ON-PAY VOTES ISSUER 10123824 0 1 YEAR 10123824 FOR PROTARA THERAPEUTICS, INC. 74365U107 US74365U1079 06/12/2026 Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 PROTARA THERAPEUTICS, INC. 74365U107 US74365U1079 06/12/2026 Vote, on an advisory basis, as to whether the stockholder advisory vote to approve the compensation of our named executive officers, (i.e., Proposal 3) should occur every one, two or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 RELAY THERAPEUTICS, INC. 75943R102 US75943R1023 06/09/2026 To consider and act upon an advisory vote on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 REPLIMUNE GROUP INC 76029N106 US76029N1063 09/03/2025 To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 11045336 0 FOR 11045336 FOR REVOLUTION MEDICINES, INC. 76155X100 US76155X1000 06/18/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 RHYTHM PHARMACEUTICALS, INC. 76243J105 US76243J1051 06/24/2026 Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 5604483 0 FOR 5604483 FOR ROIVANT SCIENCES LTD. G76279101 BMG762791017 09/10/2025 To cast a non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 SKYE BIOSCIENCE, INC. 83086J309 US83086J3095 05/26/2026 Consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission. SECTION 14A SAY-ON-PAY VOTES ISSUER 1253802 0 FOR 1253802 FOR STOKE THERAPEUTICS, INC. 86150R107 US86150R1077 06/03/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 407974 0 FOR 407974 FOR STRUCTURE THERAPEUTICS, INC. 86366E106 US86366E1064 06/17/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 SUMMIT THERAPEUTICS INC. 86627T108 US86627T1088 06/10/2026 Approval, by a non-binding advisory vote, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 TAYSHA GENE THERAPIES, INC. 877619106 US8776191061 06/01/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 TAYSHA GENE THERAPIES, INC. 877619106 US8776191061 06/01/2026 To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 TECTONIC THERAPEUTIC, INC. 878972108 US8789721086 06/08/2026 Advisory approval of the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ULTRAGENYX PHARMACEUTICAL INC. 90400D108 US90400D1081 05/14/2026 Advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 VENTYX BIOSCIENCES, INC. 92332V107 US92332V1070 03/03/2026 To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosciences, Inc. to its named executive officers in connection with the merger of merger sub with and into Ventyx Biosciences, Inc.; and SECTION 14A SAY-ON-PAY VOTES ISSUER 2349280 0 FOR 2349280 FOR VERASTEM, INC. 92337C203 US92337C2035 05/21/2026 To approve an advisory vote on the compensation of the named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 VIRIDIAN THERAPEUTICS, INC. 92790C104 US92790C1045 06/02/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 VIRIDIAN THERAPEUTICS, INC. 92790C104 US92790C1045 06/02/2026 To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 VTV THERAPEUTICS INC. 918385204 US9183852048 06/26/2026 To approve, on an advisory basis, the compensation of our named executive officers, as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 WAVE LIFE SCIENCES, INC. 94352A104 US94352A1043 08/05/2025 To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 WAVE LIFE SCIENCES, INC. 94352A104 US94352A1043 08/05/2025 To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 XENCOR, INC. 98401F105 US98401F1057 06/16/2026 Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers, as disclosed in this Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 XENON PHARMACEUTICALS INC. 98420N105 CA98420N1050 06/02/2026 To approve, on an advisory basis, the compensation of the Corporation's named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 XENON PHARMACEUTICALS INC. 98420N105 CA98420N1050 06/02/2026 To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0